Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Deciphera Pharmaceuticals (United States)

deciphera.comROR OpenAlex
Research works
71
▲ 192% vs 2018-21
Citations
1.1k
15.8 per fractional work
Top-10% rate
16.9%
all institutions 10.0%
Open access
36%
world 40%
International
17%
world 18%
Deciphera Pharmaceuticals (United States)

Not ranked overall: Deciphera Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Deciphera Pharmaceuticals (United States) work in?

In 2022-now, 54% of research at Deciphera Pharmaceuticals (United States) is in Health Sciences, 37% in Life Sciences. Its largest fields are Medicine (54%), Biochemistry, Genetics and Molecular Biology (35%), Chemistry (3%). It does 2.1× the world's share of Life Sciences.

Health Sciences: 18 fractional works · 54.5% of its workMedicine: 18 fractional works · 54.5% of its workGastroenterology: 4 fractional works · 11.5% of its workPulmonary and Respiratory Medicine: 4 fractional works · 11.2% of its workOncology: 3 fractional works · 10.4% of its workRheumatology: 3 fractional works · 7.9% of its workHematology: 1 fractional works · 3.8% of its workGenetics: 1 fractional works · 2.2% of its workEpidemiology: 1 fractional works · 1.8% of its workPathology and Forensic Medicine: 0 fractional works · 1.5% of its workSurgery: 0 fractional works · 1.0% of its workRehabilitation: 0 fractional works · 0.7% of its workNeurology: 0 fractional works · 0.6% of its workPhysiology: 0 fractional works · 0.5% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.3% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.3% of its workLife Sciences: 12 fractional works · 37.4% of its workBiochemistry, Genetics and Molecular Biology: 12 fractional works · 35.1% of its workMolecular Biology: 6 fractional works · 18.9% of its workCell Biology: 3 fractional works · 9.7% of its workCancer Research: 1 fractional works · 2.0% of its workGenetics: 0 fractional works · 1.5% of its workBiotechnology: 0 fractional works · 1.3% of its workBiochemistry: 0 fractional works · 1.0% of its workEndocrinology: 0 fractional works · 0.7% of its workImmunology and Microbiology: 1 fractional works · 2.4% of its workImmunology: 1 fractional works · 2.4% of its workPhysical Sciences: 3 fractional works · 8.1% of its workChemistry: 1 fractional works · 3.0% of its workOrganic Chemistry: 1 fractional works · 3.0% of its workEngineering: 1 fractional works · 3.0% of its workMechanical Engineering: 1 fractional works · 1.8% of its workBiomedical Engineering: 0 fractional works · 1.3% of its workChemical Engineering: 0 fractional works · 1.0% of its workProcess Chemistry and Technology: 0 fractional works · 1.0% of its workComputer Science: 0 fractional works · 1.0% of its workComputational Theory and Mathematics: 0 fractional works · 1.0% of its workALL ITS WORKDecipheraPharmaceuticals…33fractional works, 2022-now
Life Sciences37%Physical Sciences8%Health Sciences54%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 7 fields, with their numbers
    1. Medicine1854.5%
    1. Biochemistry, Genetics and Molecular Biology1235.1%
    2. Immunology and Microbiology12.4%
    1. Chemistry13.0%
    2. Engineering13.0%
    3. Chemical Engineering01.0%
    4. Computer Science01.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 6.58× its world share, 12 worksBiochemistry, Geneti…Immunology and Microbiology: 2.34× its world share, 1 worksImmunology and Micro…Chemical Engineering: 2.89× its world share, 0 worksChemical EngineeringChemistry: 1.93× its world share, 1 worksChemistryComputer Science: 0.13× its world share, 0 worksComputer ScienceEngineering: 0.20× its world share, 1 worksEngineeringMedicine: 2.83× its world share, 18 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.6×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology6.58×12 works
  2. Chemical Engineering2.89×0 works
  3. Medicine2.83×18 works
  4. Immunology and Microbiology2.34×1 works
  5. Chemistry1.93×1 works
  6. Engineering0.20×1 works
  7. Computer Science0.13×0 works

Who are the top researchers at Deciphera Pharmaceuticals (United States)?

Ranked on the quality score, Rodrigo Ruiz‐Soto, Bryan D. Smith and Michael D. Kaufman lead among researchers whose main affiliation is Deciphera Pharmaceuticals (United States).

  1. 1 Rodrigo Ruiz‐Soto United States · #227,949 worldwide 2.4k citations · 95 works
  2. 2 Bryan D. Smith United States · #278,194 worldwide 2.4k citations · 150 works
  3. 3 Michael D. Kaufman United States · #497,478 worldwide 5.6k citations · 157 works
  4. 4 Molly M. Hood United States · #560,381 worldwide 1.3k citations · 46 works
  5. 5 Scott Wise United States · #568,252 worldwide 2.6k citations · 135 works
  6. 6 Daniel Lee Flynn United States · #618,443 worldwide 4.3k citations · 209 works
  7. 7 Cynthia B. Leary United States · #657,572 worldwide 729 citations · 47 works
  8. 8 Subha Vogeti United States · #806,354 worldwide 936 citations · 27 works
  9. 9 Ying Su United States · #867,493 worldwide 1k citations · 35 works
  10. 10 Lakshminarayana Vogeti United States · #952,287 worldwide 927 citations · 28 works
All ranked researchers at Deciphera Pharmaceuticals (United States)

What are the most cited papers from Deciphera Pharmaceuticals (United States)?

The most cited paper from Deciphera Pharmaceuticals (United States) is "Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial" (Jean‐Yves Blay, César Serrano, Michael Charles Heinrich et al., 2020), with 430 citations. Next come "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers" (312) and "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants" (285).

Most cited papers
#PaperReleasedCitations
1 Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial Jean‐Yves Blay, César Serrano, Michael Charles Heinrich et al. · The Lancet Oncology Open access 5 Jun 2020 430
2 Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Sheng-Bin Peng et al. · Cancer Cell Open access Sep 2015 312
3 Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants Bryan D. Smith et al. · Cancer Cell Open access May 2019 285
4 Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Ethan Basch, Claus C. Becker, Lauren J. Rogak et al. · Clinical Trials Open access Dec 2020 256
5 Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Wayne W. Chan et al. · Cancer Cell Open access Apr 2011 213
All 60 most cited papers, with filters and sorting

Which keywords describe research at Deciphera Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Prognostic Factors, Chemotherapy, Cancer Therapy, PET Imaging, Imatinib Mesylate, Sunitinib, Apoptosis and Cell Death.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 38 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 38 words, with their numbers
  1. Prognostic Factors6▲ 41×4 topics
  2. Chemotherapy5▲ 20×8 topics
  3. Cancer Therapy4▲ 22×7 topics
  4. PET Imaging4▲ 72×3 topics
  5. Imatinib Mesylate4▲ 233×1 topic
  6. Sunitinib4▲ 420×1 topic
  7. Apoptosis4▲ 35×5 topics
  8. Cell Death3▲ 42×3 topics
  9. Cancer3▲ 7.1×13 topics
  10. Oxidative Stress3▲ 5.6×3 topics
  11. Clinical Practice Guidelines3▲ 17×2 topics
  12. Radiotherapy3▲ 20×5 topics
  13. Endoplasmic Reticulum2▲ 279×1 topic
  14. Stress2▲ 21×1 topic
  15. Imaging2▲ 27×3 topics
  16. Inflammation2▲ 3.2×9 topics
  17. Pigmented Villonodular Synovitis2▲ 441×1 topic
  18. Synovial Chondromatosis2▲ 441×1 topic
  19. Tumor Microenvironment2▲ 14×5 topics
  20. Osteosarcoma2▲ 120×1 topic
  21. Soft Tissue Sarcoma2▲ 106×1 topic
  22. Proteasome Inhibitors2▲ 75×2 topics
  23. Immunotherapy2▲ 6.8×6 topics
  24. Metabolism2▲ 8.7×5 topics
  25. Gene Expression1▲ 6.9×4 topics
  26. Immune Response1▲ 6.9×2 topics
  27. Endoscopic Resection1▲ 36×1 topic
  28. Gastric Cancer1▲ 32×1 topic
  29. Survival Analysis1▲ 14×3 topics
  30. BRAF gene1▲ 179×1 topic
  31. Cetuximab1▲ 40×2 topics
  32. Fluorouracil1▲ 103×1 topic
  33. KRAS Mutations1▲ 103×1 topic
  34. MAP Kinase1▲ 179×1 topic
  35. Melanoma1▲ 53×2 topics
  36. Oncogenic Mutations1▲ 122×2 topics
  37. Precision Medicine1▲ 6.8×2 topics
  38. Immunity1▲ 7.8×3 topics

Which research topics does Deciphera Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Gastrointestinal Tumor Research and Treatment, Endoplasmic Reticulum Stress and Disease, Musculoskeletal synovial abnormalities and treatments and Sarcoma Diagnosis and Treatment.

Gastrointestinal Tumor R…4Gastrointestinal Tumor Research and Treatment: 4 fractional worksEndoplasmic Reticulum Stress and Disease: 2 fractional worksMusculoskeletal synovial abnormalities and treatments: 2 fractional worksSarcoma Diagnosis and Treatment: 2 fractional worksGastric Cancer Management and Outcomes: 1 fractional worksColorectal Cancer Treatm…1Colorectal Cancer Treatments and Studies: 1 fractional worksMelanoma and MAPK Pathways: 1 fractional worksUbiquitin and proteasome pathways: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksBiochemical and Molecular Research: 1 fractional works
GastroenterologyCell BiologyRheumatologyPulmonary and Respiratory Medicine2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Gastrointestinal Tumor Research and Treatment Gastroenterology 4 works
  2. 2 Endoplasmic Reticulum Stress and Disease Cell Biology 2 works
  3. 3 Musculoskeletal synovial abnormalities and treatments Rheumatology 2 works
  4. 4 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 2 works
  5. 5 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 1 works
  6. 6 Colorectal Cancer Treatments and Studies Oncology 1 works
  7. 7 Melanoma and MAPK Pathways Molecular Biology 1 works
  8. 8 Ubiquitin and proteasome pathways Molecular Biology 1 works
  9. 9 Cancer Immunotherapy and Biomarkers Oncology 1 works
  10. 10 Biochemical and Molecular Research Molecular Biology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available35.9%not open64.1%

World: 40% of research is openly available.

with international co-authors17.4%domestic only82.6%

World: 18% is written across borders.

How has Deciphera Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 192% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Deciphera Pharmaceuticals (United States) as a percentage of every work published that year, 0.000098% in 2024.

still counting0.00010%0.00020%Deciphera Pharmaceuticals (United States)0.000054% in 202520102020

Fractional works of Deciphera Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Deciphera Pharmaceuticals (United States). Posts are plain text and can be reported.